此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

针对顽固性2型糖尿病试验(CAPTAIN-T2D) (CAPTAIN-T2D)

2026年10月5日 更新者:Sparrow Pharmaceuticals

Clofutriben 与安慰剂针对难治性2型糖尿病的第二阶段临床试验(CAPTAIN-T2D)

CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).

研究概览

详细说明

CAPTAIN-T2D is a two-part, multicenter, randomized, double-blind, parallel group, placebo- controlled trial of the 11-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor clofutriben. The primary objectives of this trial are to characterize the relationship of clofutriben dose to improved glycemic control, and to identify one or more doses suitable for Phase 3 evaluation, in patients with T2D and elevated cortisol.

The trial consists of two parts.

Part 1 (Screening) will last between approximately 5 to 9 weeks for most participants. The screening period duration allows for (sequentially) initial eligibility screen, dexamethasone suppression test, and further eligibility assessments.

During Part 2 (Treatment), participants will be randomized to placebo or one of four clofutriben doses. Part 2 will last 24 weeks with a follow-up phone call 4 weeks after the last dose of trial medication.

研究类型

介入性

注册 (估计的)

1500

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Arizona
      • Chandler、Arizona、美国、85225
      • Tucson、Arizona、美国、85711
    • California
      • Fountain Valley、California、美国、92708
        • 招聘中
        • Ark Clinical Research - Fountain Valley
        • 接触:
      • Huntington Park、California、美国、90255
      • La Mesa、California、美国、91942
      • Long Beach、California、美国、90815
      • Los Angeles、California、美国、90057
      • Los Angeles、California、美国、90015
        • 招聘中
        • Los Angeles Institute for Metabolic Research
        • 接触:
      • Northridge、California、美国、98433
      • San Diego、California、美国、92120
    • Florida
      • Edgewater、Florida、美国、32132
      • Fort Lauderdale、Florida、美国、33312
        • 招聘中
        • The Center for Diabetes and Endocrine Care
        • 接触:
      • Miami、Florida、美国、33173
      • New Port Richey、Florida、美国、34652
      • Port Charlotte、Florida、美国、33952
        • 招聘中
        • Innovative Research Institute
        • 接触:
      • Port Orange、Florida、美国、32127
      • Winter Park、Florida、美国、32789
    • Georgia
      • Atlanta、Georgia、美国、30303
        • 招聘中
        • Emory University School of Medicine
        • 接触:
      • Columbus、Georgia、美国、31904
    • Idaho
      • Boise、Idaho、美国、83709
    • Illinois
      • Chicago、Illinois、美国、60607
        • 招聘中
        • Chicago Clinical Research Institute
        • 接触:
          • Manognya Clinical Research Manager
          • 电话号码:303 3127913241
          • 邮箱:manognya@ccrii.us
    • Iowa
      • West Des Moines、Iowa、美国、50226
        • 招聘中
        • Iowa Diabetes and Endocrinology Research Center
        • 接触:
    • Kansas
      • Wichita、Kansas、美国、67226
        • 招聘中
        • Alliance for Multispecialty Research - Wichita East
        • 接触:
    • Kentucky
      • Edgewood、Kentucky、美国、41017
    • Louisiana
      • Lafayette、Louisiana、美国、70508
      • Metairie、Louisiana、美国、70006
        • 招聘中
        • NOLA Care Clinical Research
        • 接触:
      • New Orleans、Louisiana、美国、70112
        • 招聘中
        • Tulane University School of Medicine
        • 接触:
    • Maryland
      • Rockville、Maryland、美国、20854
    • Massachusetts
      • Springfield、Massachusetts、美国、011030
    • Michigan
      • Troy、Michigan、美国、48085
        • 招聘中
        • Oakland Medical Research Center
        • 接触:
    • Nebraska
      • Lincoln、Nebraska、美国、68510
      • Omaha、Nebraska、美国、68134
    • Nevada
      • Las Vegas、Nevada、美国、89148
      • Las Vegas、Nevada、美国、89108
    • New York
      • Albany、New York、美国、12203
        • 招聘中
        • Albany Medical College
        • 接触:
    • North Carolina
      • Chapel Hill、North Carolina、美国、27514
        • 招聘中
        • University of North Carolina at Chapel Hill
        • 接触:
      • Greenville、North Carolina、美国、27834
      • Morehead City、North Carolina、美国、28557
      • Wilmington、North Carolina、美国、28401
        • 招聘中
        • PMG Research of Wilmington, LLC
        • 接触:
    • Ohio
      • Cincinnati、Ohio、美国、45219
        • 招聘中
        • Velocity Clinical Research, Cincinnati, Mt. Auburn
        • 接触:
      • Cincinnati、Ohio、美国、45242
        • 招聘中
        • Velocity Clinical Research - Cincinnati, Blue Ash
        • 接触:
      • Columbus、Ohio、美国、43201
      • Columbus、Ohio、美国、43215
        • 招聘中
        • Remington Davis, Inc
        • 接触:
    • Oregon
      • Eugene、Oregon、美国、97404
        • 招聘中
        • Willamette Valley Clinical Studies
        • 接触:
          • Patricia Manager
          • 电话号码:541-461-0132
          • 邮箱:drpatb@aol.com
    • Pennsylvania
      • West Chester、Pennsylvania、美国、19380
    • South Carolina
      • Anderson、South Carolina、美国、29621
      • Mt. Pleasant、South Carolina、美国、29464
    • Texas
      • Austin、Texas、美国、78759
      • Dallas、Texas、美国、75230
      • Houston、Texas、美国、77040
      • Lampasas、Texas、美国、76550
        • 招聘中
        • Radiance Clinical Research
        • 接触:
      • Lewisville、Texas、美国、75057
      • Mission、Texas、美国、78572
        • 招聘中
        • Texas Valley Clinical Research - Mission, TX
        • 接触:
      • Round Rock、Texas、美国、78681
        • 招聘中
        • Texas Diabetes & Endocrinology, P.A. - Round Rock
        • 接触:
      • San Antonio、Texas、美国、78229
        • 招聘中
        • Diabetes & Glandular Disease Clinic, P.A.
        • 接触:
      • San Antonio、Texas、美国、78251
        • 招聘中
        • Texas Valley Clinical Research - San Antonio TX
        • 接触:
      • Seabrook、Texas、美国、77586
      • Weslaco、Texas、美国、78596
        • 招聘中
        • Texas Valley Clinical Research, LLC
        • 接触:
    • Utah
      • West Jordan、Utah、美国、84088
        • 招聘中
        • Velocity Clinical Research, Salt Lake City
        • 接触:
    • Virginia
      • Suffolk、Virginia、美国、23435
      • Vienna、Virginia、美国、22182

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • From Screening 1

    • Age at least 18 years.

    • HbA1c ≥7.5% documented within 3 months prior to Screening 1. (The historical HbA1c value must have been obtained after at least 2 months on the current [as of Screening 1] regimen).

    • Treatment with stable and adequate doses of ≥2 injectable or oral ADMs. (An ADM will be deemed stable if the dose has been the same for at least 3 months prior to Screening 1 and without change between Screening 1 and Day 1) (An ADM dose will be deemed adequate if it is at or above the maximal labelled dose, or a sub-maximal, but not starting, dose if limited by tolerability (confer with MM if less than half-maximal dose).

    • Adequate total daily insulin is defined as at least 0.3 units/kg/day. Insulin dose will be deemed stable with adjustments of up to 20% total daily dose during the 3 months prior to Screening 1 or between Screening 1 and Day 1.

    • Use of insulin pumps or insulin brand changes (e.g., due to insurance change or shortage) are to be discussed with the MM.

    • At least one of the following

      • ≥3 stable and adequate ADMs;
      • diabetes complication (retinopathy, nephropathy, neuropathy, atherosclerotic heart disease);
      • hypertension requiring ≥2 adequately dosed AHMs;
      • adequately dosed basal or basal plus prandial insulin in addition to at least 1 other ADM; and
      • adequately dosed incretin agonist (a single or combination agent counts as one ADM) in addition to at least 1 other ADM;
      • evidence or history of osteoporosis or non-traumatic fracture (e.g., vertebral body compression);
      • or established diagnosis of a neoplastic (non-malignant) source of hypercortisolism and have failed, are ineligible for, or declined surgery.

At DST • Post-DST cortisol level >1.8 µg/dL and serum dexamethasone ≥140 ng/dL. Patients with an established diagnosis of neoplastic hypercortisolism do not require a DST.

At Screening 2

  • HbA1c ≥7.5% at Screening 2. At Day 1
  • No change in, or initiation of, medications for hypertension within 1 month prior to Day 1.

Exclusion Criteria:

  • New-onset diabetes (onset <1 year in the past).

  • Unwillingness to maintain with current glucose-lowering regimen during the trial.

  • Unwillingness to adjust, add, replace, or discontinue current or other glucose-lowering medications during the trial as directed by the investigator.

  • Unwillingness to comply with CGM or other trial procedures.

  • Investigator considers the patient will otherwise be unwilling or unable to complete the trial.

  • Night-shift worker or otherwise habitually awake from 23:00 to 07:00 h.

  • Evidence for significant hypoglycemia while on their current diabetic treatment regimen(This includes episodes of symptomatic Level 3 hypoglycemia requiring external assistance for recovery, or CGM-documented prolonged [>15 min] or repeated episodes of either Level 2 hypoglycemia leading to >1%, or Level 1 hypoglycemia leading to >4%, in "time below range" within 3 months prior to Screening 1 or between Screening 1 and Day 1).

  • Any of the following in medical history:

    • Type 1 diabetes mellitus (T1D), latent autoimmune diabetes in adults (LADA), or familial forms of maturity-onset diabetes of the young (MODY);
    • A hemoglobinopathy or other condition which may interfere with measurement of HbA1c (e.g., sickle cell disease HbSS or other variants HbEE thalassemia, hemolytic anemia, recent blood transfusion);
    • Hypersensitivity or severe reaction to dexamethasone;
    • Pheochromocytoma, or suspicion thereof;
    • Anorexia, or other eating disorder;
    • Glucocorticoid resistance;
    • Multiple sclerosis;
    • Significant hepatic impairment (e.g., Child-Pugh Class B or C);
    • Idiopathic thrombocytopenic purpura;
    • Untreated or inadequately controlled moderate-to-severe sleep apnea (apnea-hypopnea index ≥15). (Patients whose condition has been well controlled with Continuous Positive Airway Pressure (CPAP) use for at least 3 months prior to Screening 1 are not excluded. Patients with a STOP-BANG score 5-8 should be referred for a sleep study outside the trial and may rescreen if found not to have moderate-to-severe sleep apnea);
    • Current alcohol consumption >14 units/week or >4 units in a single day for males, or >7 units/week or >3 units in a single day for females. (Patients with a CAGE score 2-4 should be evaluated further outside the trial and may be rescreened if found not to have an alcohol [or other substance] use disorder);
    • Untreated or inadequately controlled major depressive disorder, generalized anxiety disorder, bipolar disorder, post-traumatic stress disorder, or schizophrenia.(Patients whose condition has been well controlled with stable medical therapy, or has been asymptomatic, for at least 3 months prior to Screening 1 are not excluded); or
    • Any other medical condition (including malignancy) that is likely to interfere with trial assessments or the patient's ability to complete the trial.
    • Any of the following in medication history:
    • Any of the excluded medications listed in Section 6.9;
    • Any investigational drug within 4 weeks or within less than five times the drug's half-life, whichever is longer, prior to Screening 1 or between Screening 1 and Day 1;
    • Woman of childbearing potential (WOCBP) not willing to adhere to highly effective contraception or strict abstinence for the duration of the trial and for 90 days post completion/discontinuation; and
    • Pregnancy (including a positive urine test) or current breast feeding.

From Screening 2

• Prior probability of undiagnosed endogenous Cushing syndrome based on either of:

  • wo morning serum cortisol values after dexamethasone suppression >5.0 mcg/dL together with plasma dexamethasone >140 ng/mL; or
  • a morning serum cortisol value after dexamethasone suppression >1.8 mcg/dL, together with plasma dexamethasone >140 ng/mL and any one of the following that is not attributable to an etiology other than endogenous Cushing's syndrome:
  • supraclavicular/dorsocervical fat accumulation;
  • irounding of the face (especially compared with prior photos);
  • skin changes (violaceous striae, skin thinning, or excessive bruising);
  • proximal muscle weakness on exam; or
  • history of deep vein thrombosis/pulmonary embolism.
  • Plans for, or medically unable to forego, treatment for endogenous Cushing syndrome or ACS within the next 8 months. (For clarity, patients with EnCS or ACS, not having such treatment plans, and medically able to forego treatment for 8 months may enroll if otherwise eligible).
  • Severe, poorly controlled hypertension (mean systolic BP >160 mmHg or mean diastolic BP >100 mmHg) at Screening 2 or between Screening 2 and Day 1, including by at-home monitoring. (Such patients will be eligible to rescreen for Part 2 when they restore BP <160/100 mmHg for 1 month on a new stable medication regimen).
  • Positive urine screen for recreational drugs (except tetrahydrocannabinol (THC)).
  • Glomerular filtration rate (GFR) (determined using Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) <45 mL/min/1.73 m².
  • Poorly controlled hyperthyroidism/hypothyroidism (confirmed by TSH or Free thyroxine [fT4]).
  • Liver enzymes >3 × upper limit of normal (ULN) (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or bilirubin >1.5 × ULN.(excepting benign conditions such as Gilbert's)
  • Known hypersensitivity to clofutriben or to any of the product

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Dose 1

clofutriben .2 mg oral tablet daily

HSD-1 inhibitor

其他名称:
  • SPI-62
  • ASP3662
实验性的:Dose 2

clofutriben 2mg oral tablet daily

HSD-1 inhibitor

其他名称:
  • SPI-62
  • ASP3662
实验性的:Dose 3

clofutriben 6mg oral tablet daily

HSD-1 inhibitor

其他名称:
  • SPI-62
  • ASP3662
实验性的:Dose 4

clofutriben 12 mg oral tablet daily

HSD-1 inhibitor

其他名称:
  • SPI-62
  • ASP3662
安慰剂比较:placebo

placebo control oral tablet daily

Placebo

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Percentage of patients with both morning serum cortisol >1.8 mg/dL and morning plasma dexamethasone >=140 ng/dL (single composite endpoint) after a single dexamethasone 1 mg dose taken the prior night.
大体时间:8-10 hours after the dexamethasone 1 mg dose.

To assess prevalence in the trial population of morning cortisol non-suppression by a single dexamethasone 1 mg dose.

8-10 hours after the dexamethasone 1 mg dose.
Glycated hemoglobin A1c (%) change from baseline to Week 24 by treatment.
大体时间:24 weeks.

To assess glycated hemoglobin A1c (%) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks.

24 weeks.

次要结果测量

结果测量
措施说明
大体时间
Fasting plasma glucose (mmol/L) change from baseline to Week 24 by treatment.
大体时间:24 weeks

To assess glucose (mmol/L) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks.

24 weeks

其他结果措施

结果测量
措施说明
大体时间
To evaluate the safety of clofutriben in participants with T2D and EC.
大体时间:From enrollment until end of trial 9 month

Frequency of TEAEs (treatment-emergent adverse even) by clofutriben dose

From enrollment until end of trial 9 month

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年11月29日

初级完成 (估计的)

2027年12月31日

研究完成 (估计的)

2028年6月30日

研究注册日期

首次提交

2025年11月30日

首先提交符合 QC 标准的

2025年12月18日

首次发布 (实际的)

2025年12月22日

研究记录更新

最后更新发布 (实际的)

2026年10月6日

上次提交的符合 QC 标准的更新

2026年10月5日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅